Compare AOS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOS | PRAX |
|---|---|---|
| Founded | 1874 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 9.6B |
| IPO Year | 1994 | 2020 |
| Metric | AOS | PRAX |
|---|---|---|
| Price | $64.51 | $331.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $75.44 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 1.3M | 340.4K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | ★ 6.06 | N/A |
| EPS | ★ 3.85 | N/A |
| Revenue | ★ $3,830,200,000.00 | N/A |
| Revenue This Year | $4.51 | N/A |
| Revenue Next Year | $3.80 | $7,758.26 |
| P/E Ratio | $16.70 | ★ N/A |
| Revenue Growth | ★ 0.32 | N/A |
| 52 Week Low | $62.14 | $34.89 |
| 52 Week High | $81.87 | $354.87 |
| Indicator | AOS | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 52.86 |
| Support Level | $62.94 | $282.49 |
| Resistance Level | $67.48 | $353.83 |
| Average True Range (ATR) | 1.61 | 17.80 |
| MACD | 0.19 | 0.80 |
| Stochastic Oscillator | 44.87 | 47.50 |
A.O. Smith Corp manufactures a broad lineup of water heaters, boilers, and water treatment products. The company has two reporting segments: North America (75% of sales) and the rest of the world (25% of sales). A.O. Smith is the manufacturer of water heaters in North America for the residential and commercial markets, with approximately 37% and 54% market share, respectively. Residential water heaters account for the majority of North American sales and are distributed equally through wholesale and retail channels. The majority of A.O. Smith's international revenue is from China, a market the company entered during the mid-1990s. However, the firm announced a strategic review of its China operations.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.